Meds A-Z

Polysulfated Glycosaminoglycan

Detailed information about Polysulfated Glycosaminoglycan

Official label facts Owner quick guide first Marketing clearly labeled

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
Adequan® Injectable · official_label
openFDA case USA-USFDACVM-2025-US-055636 · adverse_reaction

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

What to watch for:

Not for use in horses intended for food
Safe use in breeding animals has not been established
Do not use in horses intended for human consumption
Safe use in breeding animals or in lactating mares has not been established
For Intramuscular use in horses only
Not for intra-articular use
Do not mix with other drugs or solvents
PSGAG is a synthetic heparinoid
do not use in dogs with known or suspected bleeding disorders
Do not exceed recommended dose or regimen
Vomiting (1 reports)
Nausea (1 reports)
Joint pain (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Safety & side effects

What to watch:

Not for use in horses intended for food
Safe use in breeding animals has not been established
Do not use in horses intended for human consumption
Safe use in breeding animals or in lactating mares has not been established
For Intramuscular use in horses only

Most reported reactions:

Vomiting (1 reports)
Nausea (1 reports)
Joint pain (1 reports)

When to call your vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:02 a.m.

Data freshness

Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:02 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC

Image coming soon

Polysulfated Glycosaminoglycan

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Not available

Form: Liquid (Solution)

Identifiers:

NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141038 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/140901 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

High: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (3) · Vomiting, Nausea, Diarrhea Skin & allergy (2) · Itching, Hives Neurologic (1) · Tiredness (lethargy) Effectiveness (1) · Partial lack of efficacy Other (25) · Pain NOS, Not eating, Neutrophilia

Most Reported Reactions

Body system	Cases	Species	Serious cases
Digestive	1	Dog	1
Digestive	1	Cat	1
Other	1	Cat	1
Skin & allergy	1	Dog	1
Skin & allergy	1	Dog	1
Other	1	Cat	1
Other	1	Cat	1
Other	1	Dog	1

Species coverage: Dog (20) Cat (12)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Digestive	Dog	Serious	-	1
Neurologic	Cat	Non-serious	-	1
Effectiveness	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Digestive	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Skin & allergy	Dog	Serious	-	1
Skin & allergy	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Digestive	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-055636

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)

No owner handouts linked yet.

Official label / PI (0)

No official label or package insert links yet.

SPL (4)

Adequan® Canine · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1867/Adequan%C2%AE%20Canine
Adequan® i.m. Multi-Dose · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1205/Adequan%C2%AE%20i.m.%20Multi-Dose
Adequan® i.m. · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1204/Adequan%C2%AE%20i.m.
Adequan® Injectable · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1446/Adequan%C2%AE%20Injectable

FOI (4)

N141038_Orig_7_15_1997.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/3696
N140901_Supp_9_12_1996.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/2489
N140901 Orig_11_11_1989.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/2487
UCM367650.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/413

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/3696 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1867/Adequan%C2%AE%20Canine · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/2489 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/2487 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1205/Adequan%C2%AE%20i.m.%20Multi-Dose · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1204/Adequan%C2%AE%20i.m. · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/413 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1446/Adequan%C2%AE%20Injectable · document · SPL

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:02 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: Adequan® Canine Adequan® Injectable Adequan® i.m. Multi-Dose Adequan® i.m.

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Adults, Dog, Horse

Rx/OTC: RX

Form/route: Liquid (Solution) • Intra-Articular, Intramuscular

Applications: NADA 141-038 • NADA 140-901 • NADA 136-383

Documents: 4 (FOI: 4) • SPL: 4 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 26 • Cat 16 • View

Case summaries: 10 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Lameness (undifferentiated) Trauma (HBC, falls, bite wounds)

Linked using: Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)

Top reaction signals

Vomiting (1) Nausea (1) Joint pain (1) Itching (1) Hives (1) Hiding (1) General illness (1) Facial oedema (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797

Package NDC	Product NDC	Status
10797-959-01	10797	-
10797-975-01	10797	-
10797-975-02	10797	-
10797-995-01	10797	-
10797-995-70	10797	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

N141038_Orig_7_15_1997.pdf • FOI summary • Official • June 28, 2018
FDA FOI summary for application 141038
N140901 Orig_11_11_1989.pdf • FOI summary • Official • Dec. 7, 2017
FDA FOI summary for application 140901
N140901_Supp_9_12_1996.pdf • FOI summary • Official • Dec. 7, 2017
FDA FOI summary for application 140901
UCM367650.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 136383

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 7 Clinical 0 Manufacturer 0 Marketing 0

Current Field Facts

contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-02-12)
side_effects: Top reported reactions (openFDA): Vomiting, Diarrhoea, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Not eat… (Official, 2026-02-12)
usage: Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal join… (Official, 2026-02-12)

Recent Revisions

side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Adequan® Canine RX Polysulfated Glycosaminoglycan Liquid (Solution) • Intramuscular Label highlights Official documents	American Regent, Inc.	NADA 141-038	Approved	Jun 28, 2018
Adequan® i.m. Multi-Dose Adequan® i.m. RX Polysulfated Glycosaminoglycan Liquid (Solution) • Intramuscular Label highlights Official documents	American Regent, Inc.	NADA 140-901	Approved	Dec 7, 2017
Adequan® Injectable RX Polysulfated Glycosaminoglycan Liquid (Solution) • Intra-Articular Label highlights Official documents	American Regent, Inc.	NADA 136-383	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each mL of solution contains 100 mg polysulfated glycosaminoglycan.

Dogs

Indication

For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Dosage

2 milligrams per pound of body weight (0.02 mL/lb or 1 mL/ 50 lb) by intramuscular injection. Administer intramuscularly twice weekly for up to 4 weeks (maximum of 8 injections).

Limitations

PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Adults

Composition / specifications

Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.

Horses

Indication

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

Dosage

500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.

Limitations

Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production

Composition / specifications

Each 1-milliliter ampule of sterile aqueous solution contains 250 milligrams of polysulfated glycosaminoglycan.

Horses

Indication

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.

Dosage

250 milligrams intra-articular use once a week for 5 weeks. The joint area must be shaved, cleaned, and sterilized as in a surgical procedure prior to injection. If the joint reacts with excessive inflammation, after intra-articular treatment, cease therapy.

Limitations

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents

FOI N141038_Orig_7_15_1997.pdf

Summary

AdequanÂ® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

SPL Packages

Adequan® Canine (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI N140901_Supp_9_12_1996.pdf

Summary

This supplemental application amends the NADA to provide for the use of AdequanÂ® i.m. in the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the hock joint in horses.
FOI N140901 Orig_11_11_1989.pdf

Summary

AdequanÂ® i.m. is recommended for the intramuscular treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.

SPL Packages

Adequan® i.m. Multi-Dose (ZIP)
Adequan® i.m. (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM367650.pdf

Summary

Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.

SPL Packages

Adequan® Injectable (ZIP)

FDA page: Open in Animal Drugs @ FDA

Usage

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Vomiting (1) • Dog Nausea (1) • Cat Diarrhea (1) • Cat

Showing top 5 for Digestive.

Skin & allergy

Itching (1) • Dog Hives (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic

Tiredness (1) • Cat

Showing top 5 for Neurologic.

Effectiveness

Partial lack of efficacy (1) • Dog

Showing top 5 for Effectiveness.

Other

Pain NOS (1) • Dog Not eating (1) • Dog Neutrophilia (1) • Dog Muscle atrophy (1) • Dog Monocytosis (1) • Dog

Show more (20)

Malaise (1) • Cat Listless (1) • Dog Joint pain (1) • Cat Hiding (1) • Cat Hepatomegaly (1) • Dog General illness (1) • Cat Fever (1) • Dog Falling (1) • Dog Facial oedema (1) • Dog Eosinopenia (1) • Dog Elevated symmetrical dimethylarginine (1) • Cat Elevated globulins (1) • Dog Elevated creatinine (1) • Cat Difficulty standing (1) • Dog Decreased haematocrit (1) • Cat Decreased drinking (1) • Dog Death (1) • Cat Cardiac arrest (1) • Cat Anaphylaxis (1) • Dog Abnormal radiograph finding (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Shepherd Dog - German, Male, 5.8 year, 40.82 kilogram • Drug: MSK, Unknown • Reactions: Sneezing, Listless, Not eating, Reduced responses, Difficulty standing… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-055636
Serious AE: No
Treated For AE: Yes
Sex: Male
Age: 5.80 Year
Weight: 40.820 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Sneezing Listless Not eating Reduced responses Difficulty standing Falling Polyuria Decreased drinking Fever Tachycardia Tachypnoea Weight loss Stress leukogram Neutrophilia Monocytosis Eosinopenia Elevated globulins Abnormal radiograph finding Hepatomegaly Proprioception deficit Muscle atrophy Pain NOS

Outcomes: Ongoing

Cat, Cat (unknown), Female, 20.5 year • Drug: MSK, Unassigned, Unknown • Reactions: General illness, Hiding, Joint pain, Elevated creatinine, Elevated symmetrical dimethylarginine… • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-055646
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 20.50 Year

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

General illness Hiding Joint pain Elevated creatinine Elevated symmetrical dimethylarginine Decreased haematocrit Urinary tract infection

Outcomes: Outcome Unknown

Dog, ['Chihuahua', 'Dog (unknown)'], Male, 10.75 year, 5.715 kilogram • Drug: MSK, Solution, Subcutaneous, Dose: 0.25 mL per dose • Reactions: Anaphylaxis, Swollen face, Itching, Swollen feet • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-055955
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 10.75 Year
Weight: 5.715 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Solution
Dose: 0.25 mL per dose

Reactions Reported:

Anaphylaxis Swollen face Itching Swollen feet

Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Male, 13 year, 6.804 kilogram • Drug: MSK, Solution, Subcutaneous, Dose: 0.50 mL per dose, Frequency: 1 per week • Reactions: Nausea, Prolonged one stage prothrombin time, Prolonged activated partial thrombin time, Cardiac arrest, Death • Outcome: Died

Report ID: USA-USFDACVM-2025-US-055853
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 13.00 Year
Weight: 6.804 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Solution
Dose: 0.50 mL per dose
Frequency: 1 per week

Reactions Reported:

Nausea Prolonged one stage prothrombin time Prolonged activated partial thrombin time Cardiac arrest Death

Outcomes: Died

Dog, Crossbred Canine/dog, Male, 8 year, 10.569 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Shaking, Seizure NOS, Diarrhea, Vomiting • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-054899
Serious AE: Yes
Treated For AE: No
Sex: Male
Age: 8.00 Year
Weight: 10.569 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Shaking Seizure NOS Diarrhea Vomiting

Outcomes: Recovered/Normal

Dog, Bulldog - English, Male, 6 year, 32.659 kilogram • Drug: MSK, Injection, solution, Unknown • Reactions: Partial lack of efficacy • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-053131
Serious AE: No
Treated For AE: No
Sex: Male
Age: 6.00 Year
Weight: 32.659 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Injection, solution

Reactions Reported:

Partial lack of efficacy

Outcomes: Ongoing

Dog, ['Bulldog - English', 'Retriever - Labrador'], Male, 11 year, 30.844 kilogram • Drug: MSK, Solution, Subcutaneous, Dose: 1.40 mL per dose • Reactions: Anaphylaxis, Facial oedema, Hives • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-052943
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 11.00 Year
Weight: 30.844 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Solution
Dose: 1.40 mL per dose

Reactions Reported:

Anaphylaxis Facial oedema Hives

Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Male, 12 year, 6.35 kilogram • Drug: MSK, Parenteral • Reactions: Vomiting • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-051052
Serious AE: No
Treated For AE: No
Sex: Male
Age: 12.00 Year
Weight: 6.350 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Parenteral

Reactions Reported:

Vomiting

Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Polysulfated Glycosaminoglycan

Add to My Pet's Meds

Reviewed / Updated / Sources

Pet Owner Quick Guide